MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jnha.2025.100671

Медицинская библиотека · The journal of nutrition, health & aging · 2025

The gut-liver axis in progressive steatotic liver disease: A focus on bile acid dysregulation.

Louca Panayiotis, Pericàs Juan M, Lin Yu, Kouraki Afroditi, Estévez-Vázquez Olga, Martínez-Gómez María, Cusidó M Serra, Simpson Joanna P, Cubero Francisco Javier, Homer Natalie Z M, Valdes Ana M, Menni Cristina

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The gut-liver axis regulates metabolic homeostasis, with bile acids (BAs) serving as key signalling molecules. BA dysregulation is implicated in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- and alcohol-associated liver disease (MetALD), yet consistent identification of BA markers and their mechanistic roles across different stages of these diseases remain elusive.

METHODS

We integrated three complementary studies to examine BA dysregulation: a population-based cohort (1522 females from TwinsUK with serum BA and liver biomarker data), a clinical cohort (30 patients with steatotic liver disease, fibrosis stages F0-F4, and 4 controls), and rodent models (20 rats with MASLD/MetALD vs. 9 controls). BA profiles were quantified via LC-MS.

RESULTS

The primary bile acid taurocholate was consistently correlated with liver pathology: in TwinsUK, it associated with ALT (β [95%CI] 1.81 [1.27, 2.36], FDR < 0.05) both overall and when stratifying for age (<65 years, n = 923; ≥65 years, n = 599); in the clinical cohort, it was associated with F3 fibrosis (OR [95%CI] 8.56 × 10-10 [3.80 × 10-13, 1.93 × 10-6], FDR < 0.05); and in rodents, it was associated with MASLD/MetALD (OR [95%CI] 2.86 [1.17, 9.51], FDR < 0.05). The secondary bile acid taurochenodeoxycholate was associated with both early (F0, OR [95%CI] 13.63 [1.04, 179.17], p < 0.05) and advanced stages of disease (rodents, OR [95%CI] 15.41 [2.94, 311.82], FDR < 0.05).

CONCLUSION

Taurocholate and taurochenodeoxycholate emerge as consistent BA markers across liver disease stages, suggesting BA metabolism as potential therapeutic targets. This multi-model study bridges knowledge gaps in BA-driven mechanisms, informing personalised strategies for SLD management.

Для цитирования: Louca Panayiotis, Pericàs Juan M, Lin Yu, Kouraki Afroditi, Estévez-Vázquez Olga, Martínez-Gómez María, Cusidó M Serra, Simpson Joanna P, Cubero Francisco Javier, Homer Natalie Z M, Valdes Ana M, Menni Cristina. The gut-liver axis in progressive steatotic liver disease: A focus on bile acid dysregulation.. The journal of nutrition, health & aging. 2025. DOI: 10.1016/j.jnha.2025.100671.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.